MedTrace Logo

The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans

NCT01953393 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-10-01

No results posted yet for this study

Summary

Type 2 diabetes is characterized by increased insulin resistance and impaired insulin secretion. In addition, type 2 diabetes is associated with low grade inflammation indicated by increased levels of proinflammatory cytokines such as TNF-α. TNF-α has previously been shown to impair peripheral insulin signaling in vitro and in vivo. However, it is unclear whether TNF-α may also affect endogenous glucose production (EGP) during fasting and glucose stimulated insulin secretion (GSIS) in vivo.

We hypothesized that low dose TNF-α would increase EGP and attenuate GSIS. Recombinant human TNF-α or placebo was infused in healthy, non-obese and non-diabetic young men (n=10) during a 4-hour basal period followed by an intravenous glucose tolerance test (IVGTT).

Conditions

  • Diabetes Type 2

Interventions

OTHER

Low-dose TNF-alpha

Sponsors & Collaborators

  • Copenhagen Muscle Research Centre, Rigshospitalet, Copenhagen, Denmark

    collaborator UNKNOWN

  • University of Copenhagen

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Christian P Fischer, MD · Rigshospitalet, Denmark

Study Design

Purpose
BASIC_SCIENCE

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2006-05-31
Completion
2006-10-31

Countries

  • Denmark

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01953393 on ClinicalTrials.gov